JPRN-UMIN000004677已完成2 期
Phase II study of S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer. - S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer.
Shinshu University thoracic surgery0 个研究点目标入组 55 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Besides the above
研究者
相似试验
进行中（未招募）
不适用
Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study - XELOX-TARAVEUCTR2005-005548-21-ITCONSORZIO ONCOTECH
已完成
2 期
Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+BevacizumabColorectal cancerJPRN-UMIN000015098Gunma University Graduate School40
已完成
2 期
Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancerColorectal cancerJPRN-UMIN000009083Aichi Cancer Center Hospital, Department of Clinical Oncology30
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE